ETB scientists bring unique expertise and diverse interests to research projects and collaborations to help kick-start the early discovery pathway. The team creates tools and technologies that enable the de-risking of potential targets and modalities for treating diseases. Learn more about ETB.
-
Research
-
- Funding & Notices
-
- News & Media
- About Translation
-
- About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- Stem Cell Translation Laboratory
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- Early Translation Branch (ETB)
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- A Translational Approach to Addressing COVID-19
- Antiviral Program for Pandemics
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes
- Multidisciplinary Machine-Assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey
- National COVID Cohort Collaborative (N3C)
- The Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (BGTC)
- NIH Common Fund Programs
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Functional Genomics Lab
- Therapeutics for Rare and Neglected Diseases (TRND)
- About NCATS
- Home
- About NCATS
- NCATS Programs & Initiatives
- Early Translation Branch (ETB)
Early Translation Branch (ETB)
High-Throughput Screening Helps Advance Melanoma Therapy
Finding the right compounds for new uses in treating a disease or improving a therapeutic approach can be time consuming. To speed up the process, NCATS scientists used high-throughput screening to help advance a therapy for melanoma.
NCATS created a new resource for scientists, the OpenData Portal, to openly and quickly share COVID-19-related drug repurposing data and experiments for all approved drugs.
Immunotherapy holds immense power in harnessing the body’s immune system to fight diseases. Researchers have shown a novel type of immune therapy can reprogram immune cells to stop tumor growth and kill cancer cells.
About ETBFind out more about how ETB experts help discover novel small molecule therapies across the spectrum of human diseases.
Scientific CapabilitiesAccess a collaborative team of experts in assay development, high-throughput screening, medicinal chemistry, informatics and drug development.
Work with ETBLearn how to collaborate with ETB staff to pursue a drug target or screen of interest.
Find out more about how ETB experts help discover novel small molecule therapies across the spectrum of human diseases.
Access a collaborative team of experts in assay development, high-throughput screening, medicinal chemistry, informatics and drug development.
Learn how to collaborate with ETB staff to pursue a drug target or screen of interest.
Work with Us
ETB is highly collaborative and always encourages new partnership opportunities, including projects with NIH and external researchers as well as disease foundations and biotechnology companies. Learn more about how to work with us.
Looking for a chemical probe?
ETB experts have developed many small molecule probes for further therapeutic development.
NCATS Programs & Initiatives
- News & Media
- Funding & Notices
-